Study Summary
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Want to learn more about this trial?
Request More InfoInterventions
UB-VV111GENETIC
UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
rapamycinDRUG
Rapamycin is an FDA-approved drug.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope | Duarte | California | United States |
| The David and Etta Jonas Center for Cellular Therapy | Chicago | Illinois | United States |
| Washington University School of Medicine/Siteman Cancer Center | St Louis | Missouri | United States |
| University of Nebraska Medical Center | Omaha | Nebraska | United States |
| University of Cincinnatti Medical Center | Cincinnati | Ohio | United States |
| Fred Hutch Cancer Center | Seattle | Washington | United States |
| Royal North Shore Hospital | Saint Leonards | New South Wales | Australia |
| St. Vincent's Hospital Melbourne | Fitzroy | Victoria | Australia |